Pfizer has won the bidding war against Novo Nordisk to acquire obesity-drug biotech Metsera. The pharma giant upped its offer ...

Pfizer has clinched a deal worth up to $10bn to buy weight-loss start-up Metsera, capping a dramatic takeover battle after ...

Pfizer Inc. has agreed to buy Metsera Inc. in a $10 billion deal, following a heated bidding war with Novo Nordisk A/S for ...

Revised transaction values Metsera at up to $86.25 per share Metsera's Board of Directors unanimously recommends that Metsera stockholders approve the ...

Obesity drug developer Metsera said on Friday that it had accepted Pfizer's $10 billion acquisition offer, in what could ...

The new offer improves upon Pfizer’s earlier proposal for US$86.20 (RM359.97) a share including milestone payments, said the ...

Pfizer has submitted a sweetened bid for Metsera, an obesity drug developer, as its fight against rival Novo Nordisk ...

NEW YORK/LONDON (Reuters) -A bidding war over U.S. biotech Metsera was coming to a head on Thursday, with Danish drugmaker ...

Democratic Senate Minority Leader Chuck Schumer proposed extending expiring health-care subsidies for one year as part of a measure to reopen the government, in a move aimed at breaking the monthlong ...

A fierce bidding war could be costly for Novo Nordisk. The stock price for Danish drugmaker Novo Nordisk (NYSE: NVO) is down more than 8% since last Friday's close. What's going on with this former ...

Pfizer faces a fierce bidding war with Novo Nordisk over Metsera while securing a landmark U.S. drug pricing deal.

During a press conference to announce a drug price deal for GLP-1s, President Donald Trump asked for more details about the ...